Atsena Therapeutics Doses First Patient in Phase I/II Clinical Trial of ATSN-201 for Treatment of X-Linked Retinoschisis

ATSN-201 leverages novel spreading capsid to overcome challenges associated with intravitreally delivered AAVs in the treatment of XLRS.

Atsena Therapeutics announced the first patient has been dosed in its Phase I/II clinical trial, the LIGHTHOUSE study, evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).

Atsena Therapeutics, founded by UF researchers Shannon and Sanford Boye, is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.

Based on innovations discovered in the College of Medicine Department of Pediatrics, ATSN-201 leverages one of the company’s novel spreading capsids, AAV.SPR, to overcome the challenges associated with intravitreally delivered AAVs in the treatment of XLRS.

The company noted that ATSN-201 leverages AAV.SPR, the company’s novel spreading capsid, to achieve therapeutic levels of gene expression in photoreceptors of the central retina while avoiding the surgical risks of foveal detachment.

Read more about Atsena Therapeutics Doses First Patient in Phase I/II Clinical Trial of ATSN-201 for Treatment of X-Linked Retinoschisis.